Skip to main content
SpringerLink
Log in

Is there a Role for Isolated Limb Perfusion With Tumor Necrosis Factor in Patients With Melanoma?

  • Editorials
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Rossi CR, Foletto M, Mocellin S, Pilati P, Lise M. Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-α and melphalan for bulky in-transit melanoma metastases. Ann Surg Oncol 2004;11:173–177.

    Article  PubMed  Google Scholar 

  2. Creech O, Krementz ET, Ryan RF, Winblad JW. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958;148:616–632.

    Article  PubMed  Google Scholar 

  3. Eggermont AM, van Geel AN, de Wilt JH, ten Hagen TL. The role of isolated limb perfusion for melanoma confined to the extremities. Surg Clin North Am 2003;83:371–384.

    Article  PubMed  Google Scholar 

  4. Kroon BBR, Fraker DL, Vrouenraets BC, Thompson JF. Isolated limb perfusion: results and complications. In: Thompson JF, Morton DL, Kroon BB, eds. Textbook of Melanoma. London: Martin Dunitz, 2004:410–28.

    Google Scholar 

  5. Lienard D, Ewalenko P, Delmotte JJ, et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52–60.

    PubMed  CAS  Google Scholar 

  6. Klaase JM, Kroon BBR, Benckhuijsen C, et al. Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities. Cancer 1989;64:616–621.

    Article  PubMed  CAS  Google Scholar 

  7. Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996;224:756–64; discussion 764–5.

    Article  PubMed  CAS  Google Scholar 

  8. Thompson JF, de Wilt JH. Isolated limb perfusion in the management of patients with recurrent limb melanoma: an important but limited role. Ann Surg Oncol 2001;8:564–565.

    Article  PubMed  CAS  Google Scholar 

  9. McKay A, Byrne DS. Recurrent limb melanoma: treatments other than isolated limb perfusion and infusion. In: Thompson JF, Morton DL, Kroon BBR, eds. Textbook of Melanoma. London: Martin Dunitz, 2004:443–8.

    Google Scholar 

  10. Kadison AS, Morton DL. Immunotherapy of malignant melanoma. Surg Clin North Am 2003;83:343–370.

    Article  PubMed  Google Scholar 

  11. Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 1998;14:238–247.

    Article  PubMed  CAS  Google Scholar 

  12. Thompson JF, Kam PCA, de Wilt JHW, Lindner P. Isolated limb infusion for melanoma. In: Thompson JF, Morton DL, Kroon BBR, eds. Textbook of Melanoma. London: Martin Dunitz, 2004: 429–437.

    Google Scholar 

  13. Noorda EM, Vrouenraets BC, Nieweg OE, et al. Safety and efficacy of isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol 2002;9:968–74.

    Article  PubMed  CAS  Google Scholar 

  14. Hill S, Fawcett WJ, Sheldon J, et al. Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion. Br J Surg 1993;80:995–7.

    Article  PubMed  CAS  Google Scholar 

  15. de Wilt JH, Manusama ER, van Tiel ST, et al. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer 1999;80:161–6.

    Article  PubMed  CAS  Google Scholar 

  16. Fraker DL, Alexander HR, Ross M. A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor (TNF) plus interferon gamma (IFN). Ann Surg Oncol 2002;9:S8.

    Article  Google Scholar 

  17. Schraffordt Koops H, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. J Clin Oncol 1998;16:2906–2912.

    Google Scholar 

  18. Olieman AF, van Ginkel RJ, Hoekstra HJ, et al. Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Ann Surg Oncol 1997;4:64–69.

    Article  PubMed  CAS  Google Scholar 

  19. van Etten B, de Vries MR, van Ijken MGA, et al. Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion. Br J Cancer 2003;88:314–319.

    Article  PubMed  CAS  Google Scholar 

  20. de Wilt JH, ten Hagen TL, de Boeck G, et al. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000;82:1000–1003.

    Article  PubMed  CAS  Google Scholar 

  21. Ruegg C, Yilmaz A, Bieler G, et al. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 1998;4:408–414.

    Article  PubMed  CAS  Google Scholar 

  22. Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003;4:429–437.

    Article  PubMed  Google Scholar 

  23. Bartlett DL, Ma G, Alexander HR, et al. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer 1997;80:2084–2090.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Erasmus MC, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

    Johannes H. W. de Wilt MD

  2. Sydney Melanoma Unit, Sydney Cancer Centre, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia

    John F. Thompson MD

  3. Department of Surgery, University of Sydney, Sydney, NSW, Australia

    John F. Thompson MD

Authors
  1. Johannes H. W. de Wilt MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John F. Thompson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Wilt, J.H.W., Thompson, J.F. Is there a Role for Isolated Limb Perfusion With Tumor Necrosis Factor in Patients With Melanoma?. Ann Surg Oncol 11, 119–121 (2004). https://doi.org/10.1245/ASO.2004.12.932

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1245/ASO.2004.12.932

Search

Navigation